It Seems Biospecifics Technologies Corp (NASDAQ:BSTC) Will Go Up. Just Reported Less Shorted Shares

June 23, 2018 - By Marguerite Chambers

Investors sentiment decreased to 0.77 in 2018 Q1. Its down 0.45, from 1.22 in 2017Q4. It is negative, as 14 investors sold BioSpecifics Technologies Corp. shares while 29 reduced holdings. 12 funds opened positions while 21 raised stakes. 3.50 million shares or 3.69% less from 3.63 million shares in 2017Q4 were reported.
Strs Ohio holds 13,000 shares. Legal And General Group Public Limited Com stated it has 926 shares. Los Angeles Cap Mgmt Equity Research Incorporated holds 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC) or 4,859 shares. Wellington Gru Inc Limited Liability Partnership holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 39,164 shares. 4,856 are owned by Manufacturers Life Comm The. Tiaa Cref Inv Mngmt Ltd Liability Company holds 32,423 shares or 0% of its portfolio. Smith Asset Group L P stated it has 0.01% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Morgan Stanley, a New York-based fund reported 26,755 shares. Rhumbline Advisers stated it has 4,983 shares. California Pub Employees Retirement Systems has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 16,771 shares. Parametric Assoc Limited Liability Company holds 0% or 9,335 shares in its portfolio. Denali Lc reported 55 shares. First Manhattan invested in 26,380 shares or 0.01% of the stock. Clarivest Asset Management Llc reported 0.02% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Deutsche Commercial Bank Ag holds 0% or 39,954 shares in its portfolio.

The stock of Biospecifics Technologies Corp (NASDAQ:BSTC) registered a decrease of 4.26% in short interest. BSTC’s total short interest was 168,500 shares in June as published by FINRA. Its down 4.26% from 176,000 shares, reported previously. With 16,900 shares average volume, it will take short sellers 10 days to cover their BSTC’s short positions. The short interest to Biospecifics Technologies Corp’s float is 3.11%.

The stock increased 4.80% or $2.01 during the last trading session, reaching $43.91. About 57,159 shares traded or 166.92% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 16.75% since June 23, 2017 and is downtrending. It has underperformed by 29.32% the S&P500.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $316.78 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 26.94 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Another recent and important BioSpecifics Technologies Corp. (NASDAQ:BSTC) news was published by which published an article titled: “Investor Expectations to Drive Momentum within Capital Product Partners, Nova Measuring Instruments, BioSpecifics …” on June 06, 2018.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.